平成 29 年
〈和文〉
1．藤岡 裕士, 泉原 昭文, 浦崎 永一郎, 原 昌司, 空田 剛彦, 中村 龍二, 松尾 秀徳, 山下勝 弘 ： 脳 卒中 後 の治 療介 入 時 期 に着 目 した 運動 野 刺 激 療法 の 上肢 麻痺 改 善 効 果

AFeasibility and Safety Study 臨床神経生理学 45：1-9；2017
2．松尾秀徳：免疫性神経疾患のアフェレシス療法・日本急性血液浄化学会雑誌 8：15-20・
2017
3．中根 俊成(熊本大学 大学院生命科学研究部神経内科学), 松尾 秀徳, 安東 由喜雄：
【自己免疫性脳炎に対するアフェレシス】 VGKC 複合体抗体関連疾患の病態とその治療 日本アフェレシス学会雑誌 36：27-31；2017
4．松尾秀徳：特集 神経内科医が知っておくべき重症筋無力症（MG）の知識 4.重症筋無力症の治療①標準的な治療・日常診療と神経免疫１ Ｐ54-64・2017 年5．松尾秀徳、津田真実：神経救急・集中治療のための緊急血液浄化法・神経救急・集中治療ハンドブック第 2 版Ｐ543-554・2017 年
6．福留 隆泰, 吉村 峻祐, 白石 裕一, 本村 政勝：【神経筋接合部の生理学:update】
Lambert-Eaton 筋無力症候群 update(解説/特集)

神経内科 87 巻 4 号 Page404-410

7．成田智子 白石裕一 本村政勝：重症筋無力症およびクリーゼ

神経救急・集中治療

ハンドブック第 2 版 P297-308〈英文〉
1．Ishikawa H, Taniguchi A, Ii Y, Higuchi O, Matsuo H, Nakane S, Asahi M, Niwa A,
Tomimoto H.：Double-seropositive myasthenia gravis with acetylcholine receptor and lowdensity lipoprotein receptor-related protein 4 antibodies associated with invasive thymoma.
Neuromuscul Disord. 2017 27:914-917.
2 ． Jafarnezhad-Ansariha F, Yekaninejad MS, Jamshidi AR, Mansouri R, Vojdanian M,Mahmoudi M, Fattahi MJ, Hashemi SN, Rehm BHA, Matsuo H, Esposito E, Cuzzocrea S,
Mirshafiey A.：The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1and COX2 activities and gene expression in ankylosing spondylitis patients and the murine
monocyte/macrophage, J774cellline.Inflammopharmacology. 2017Aug 17.

doi:

10.1007/s10787-017-0386-4. [Epub ahead of print]
3．Mirshafiey A, Taeb M, Mortazavi-Jahromi S, Jafarnezhad-Ansariha F, Rehm BHA, Esposito
E, Cuzzocrea S, Matsuo H.：Introduction of β-d-mannuronic acid (M2000) as a novel
NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene
expression.Pharmacol

Rep.

2017

Apr

25.

pii:

S1734-1140(17)30168-8.

doi:

10.1016/j.pharep.2017.04.015. [Epub ahead of print]PMID:28951072
4．Ahmadi H, Jamshidi AR, Mahmoudi M, Cuzzocrea S, Fattahi MJ, Barati A, Rehm BHA,Matsuo H, Mirshafiey A.：The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000)

as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide
Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid
Arthritis.Curr Drug Discov Technol. 2017;14:206
5．Sakai W, Nakane S, Urasaki E, Toyoda K, Sadakata E, Nagaishi A, Fukudome T, Yamakawa
Y, Matsuo H.：The Cross-Sectional Area of Paraspinal Muscles Predicts the Efficacy of Deep
Drain Stimulation for Camptocormia.J Parkinsons Dis. 2017;7:247-253.
6．Nakane S, Mukaino A, Maeda Y, Higuchi O, Matsuo H, Ando Y. ：Extra-autonomic
manifestations in autoimmune autonomic ganglionopathy: a Japanese survey.J Neurol
Neurosurg Psychiatry. 2017 88:367-368.
7．Maeda Y, Nakane S, Higuchi O, Nakamura H, Komori A, Migita K, Mukaino A, Umeda
M, Ichinose K, Tamai M, Kawashiri SY, Sakai W, Yatsuhashi H, Kawakami A, Matsuo H.：
Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases
including primary biliary cirrhosis.Mod Rheumatol. 2017;27: 664-668.
8．Fattahi MJ, Jamshidi AR, Mahmoudi M, Vojdanian M, Yekaninejad MS, JafarnezhadAnsariha F, Ahmadi H, Rehm BHA, Matsuo H, Cuzzocrea S, Hosseini M, Hashemi SN,Aghazadeh Z, Mirshafiey A.：Evaluation of the efficacy and safety of β-d-mannuronic acidin patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II
clinical trial. Int Immunopharmacol. 2017 N
9．Sakai W, Nakane S, Urasaki E, Toyoda K, Sadakata E, Nagaishi A, Fukudome T, Yamakawa
Y, Matsuo H.：The Cross-Sectional Area of Paraspinal Muscles Predicts the Efficacy of Deep
Drain Stimulation for Camptocormia.・J Parkinsons Dis. 2017 Jan 30.
10．Writing Group; Edaravone (MCI-186) ALS 19 Study Group.：Safety and efficacy ofedaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, doubleblind,placebo-controlled

trial. ｍ Lancet

Neurol.

2017

Jul;16(7):505-512.

doi:

10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
11．Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J,Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN
Study Group.：Safety and efficacy of eculizumab in anti-acetylcholine receptor antibodypositive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, doubleblind, placebo-controlled, multicentre study.Lancet Neurol. 2017 Dec;16(12):976-986. doi:
10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017
Dec;16(12 ):954. PMID:29066163
12．Vincent A, Huda S, Cao M, Cetin H, Koneczny I, Rodriguez-Cruz P, Jacobson L, Viegas
S, Jacob S, Woodhall M, Nagaishi A, Maniaol A, Damato V, Leite MI, Cossins J, Webster R,Palace J, Beeson D. Serological and experimental studies in different forms of myasthenia
gravis. Ann N Y Acad Sci. 2018 Feb;1413(1):143-153. doi: 10.1111/nyas.13592. Epub 2018

Jan 29. Review.